No. Study, year Country N (Total=85) Female (n) Age [MEAN (SD)] EDSS [RANGE (MEAN)] SC type Infusion method Cell count dosage injected Times
1 Bonab2012 Iran 25 19 34.7 4-6.5 MSC IT 29.5x10(6) Single
2 Connick,2012 UK 10 3 48.8 5.5-6.5 MSC IV 1.6x10(6)/KG Single
3 Odianc, 2011 Russia 8 3 37.5 3.5-6.5 (5.6) MSC IV x10(6)/kg 4-8 times
4 Karussis, 2010 Israel 15 8 35.3 4-8 (6.7) MSC IT(10), IT+IV(5) 63.2-+10(6) Single
5 Yamout, 2010 Lebanon 7 4 39.3 4.5-7.5(6.5) MSC IT+IS 3-5x10(7) Single
6 Bonab, 2007 Iran 10 0 33 3.5-6 MSC IT 8.3x10(6) Single
7 Riordan, 2009 USA 3 - 32 & 50* - SVF IV.IT 5x10 (6) Several
8 Rice, 2011 UK 6 4 45.85 4.5-6.5(5.9) BM IV 1.4X10(8) 1.1X10(6) Single
9 Linag, 2009 China 1 1 55 8.5 Al-UC-MSC IV, IT 1x107
2x107
Single
Table 2: Baseline demographic of the open-label clinical trials of Stem Cell-Based Therapy in MS; Note: EDSS: Expanded Disability Scoring System; IT: Intra-Techal; IS: Intra-Spinal; IV: Intra-Venous; *age for 2 of the 3 patients was reported by the authors.